Transformational Approach to Treating Diabetic Eye Disease

We believe patients deserve a new choice to prevent vision loss from diabetes.

A novel, topical integrin inhibitor eye drop would represent a paradigm shift in disease management.

Diabetic retinopathy (DR) is the leading cause of blindness in working age adults.1

For patients with nonproliferative DR (NPDR), current standard of care is “watch and wait” for signs of disease progression.

Rethinking Disease Management

Diabetic retinopathy in the US is projected to almost double by 20302. With no non-invasive treatments available the current standard of care is active surveillance until a sight threatening complication arises or vision deteriorates past a certain threshold at which point anti-VEGF intravitreal injections are commenced. These injections into the back of the eye are required every month or so for the rest of the patient’s life or until resistance develops. Our topical compound, OTT166, is designed to be administered as an eye drop by the patient at home to treat diabetic retinopathy earlier to preserve vision. By enabling earlier non-invasive treatment our goal is to prevent progression, thereby delaying or completely eliminating the need for intravitreal injections.

Novel Integrin Inhibitor Purposefully Designed to Distribute to the Back of the Eye to Treat Diabetic Eye Disease

Enable Treatment Earlier in Disease Process

Improve Retinal Health and Prevent Progression of Disease

Non-Invasive - Remove Barriers to Treatment For Both Patients and Prescribers

Expand Prescriber Base and Increase Access to Treatment

OTT166 is a novel small molecule selective integrin inhibitor that OcuTerra has purpose engineered to have the required physicochemical characteristics to be able to reach the retina from eye drop application. It is designed to be administered by the patient at home and thus has the potential to dramatically change the treatment paradigm by enabling earlier non-invasive treatment to preserve vision and prevent progression, thereby delaying or completely eliminating the need for intravitreal injections.

  • OcuTerra is preparing to commence Phase 2 studies in patients with moderate to severe non-proliferative diabetic retinopathy in 2021.
  • OTT166, has been studied in two separate multi-center, randomized, Phase 1b trials, in retinal disease patients and shown safety, tolerability and evidence of biological activity.

For additional information regarding the investigational product OTT166, please contact OcuTerra Therapeutics.


  1. 2020. Common Eye Disorders And Diseases | CDC. [online] Available at:​visionhealth/​basics/​ced/​index.html [Accessed 13 July 2020].
  2. Clarion Research, Inc. Data On File; 2019.